美股A股
StockGist
Back
8-K2026-04-10· glm-5

KLRS · Kalaris Therapeutics Inc

0001193125-26-151215

SEC filing

Summary

CFO Matthew Gall resigned effective April 14, 2026, and Chief Accounting Officer Brett Hagen was appointed as principal financial officer to succeed him.

Key takeaways